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Background: Monitoring left ventricular ejection fraction (EF) is customary in breast cancer patients receiving potentially cardiotoxic therapy. This 
is typically done using transthoracic echocardiography (TTE) or multigated acquisition radionuclide imaging (MUGA). MUGA is more reproducible, 
but results in exposure to ionizing radiation (IR) of approximately 8 mSv/scan. In patients treated with trastuzumab, a typical monitoring schedule 
could include up to 5 scans in a year, in addition to other diagnostic tests involving IR. Thus, sequential EF assessments required with breast cancer 
treatment may amount to considerable radiation doses. The aim of this study was to evaluate how much IR from imaging breast cancer patients are 
exposed to, and what proportion is attributable to MUGA.
Methods: Electronic records of 139 female patients diagnosed with breast cancer (age 53±12 yrs, 23 treated with trastuzumab) during 2010-
2012 were reviewed. Estimated radiation dose (ERD) was used to calculate exposure associated with imaging procedures within 12 months of first 
EF assessment.
results: The majority of patients (108/139, 78%) had at least one MUGA performed, while less than a third (31/139, 22%) had TTE only. Use of 
MUGA was most frequent in those treated with trastuzumab (20/23, 87%). Total ERD in the MUGA group was over twice that in the TTE group (32±12 
mSv vs 14±26 mSv, p<0.01 by unpaired t-test). In the MUGA group (N=108), 46 (43%) of subjects were exposed to 0-25mSv, 44 (40%) to 26-
49mSv and 18 (17%) to ≥50mSv. Only 6% were exposed to ≥50mSv in the TTE group. Over a third (34±27%) of the total ERD in the MUGA group was 
due to EF assessment.
conclusions: In our cohort, MUGA was used to monitor EF in the majority of breast cancer patients, even those treated with trastuzumab, in whom 
multiple EF assessments are indicated. This resulted in significantly higher ERD. Radiation exposure should be taken into account when method of EF 
assessment is being chosen. Alternative techniques that do not employ radiation should be strongly considered.
